Study takes ‘cool’ approach to reducing heart attack damage by longitudeadmin | Apr 25, 2013 | Portfolio News
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia by longitudeadmin | Apr 23, 2013 | Portfolio News
Civitas Therapeutics Announces Positive Phase 2 Clinical Results for CVT-301, an Inhaled L-dopa for Parkinson’s Disease by longitudeadmin | Apr 19, 2013 | Portfolio News
Collegium Pharmaceutical Announces Successful Completion of Clinical Study Evaluating the Impact of Tampering on Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Opioid Product by longitudeadmin | Apr 17, 2013 | Portfolio News
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa® by longitudeadmin | Apr 8, 2013 | Portfolio News